TIME IN THERAPEUTIC RANGE ≥55% VERSUS <55% ON WARFARIN THERAPY OUTCOMES IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS

被引：1
|
作者：
An, Jaejin [1 ]
Lang, Daniel [1 ]
Fang, Niu [1 ]
Jazdzewski, Kristin [1 ]
Le, Paul [1 ]
Rashid, Nazia [1 ]
Meissner, Brian [1 ]
Mendes, Robert [1 ]
Dills, Diana [1 ]
Ershoff, Dan [1 ]
Borok, Gerald [1 ]
Bruno, Amanda [1 ]
机构：
[1] Kaiser Permanente So Calif, Downey, CA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 63卷 / 12期
关键词：
D O I：
10.1016/S0735-1097(14)60359-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1143-114
引用
收藏
页码：A359 / A359
页数：1
相关论文
共 50 条
  • [31] Persistence of Dabigatran Versus Warfarin Therapy in Patients with Non-valvular Atrial Fibrillation in the Real-world Clinical Practice
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 382 - 382
  • [32] Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
    Breithardt, Guenter
    Baumgartner, Helmut
    Berkowitz, Scott D.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Halperin, Jonathan L.
    Singer, Daniel E.
    Hankey, Graeme J.
    Hacke, Werner
    Becker, Richard C.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    Patel, Manesh R.
    HEART, 2016, 102 (13) : 1036 - 1043
  • [33] WARFARIN DISCONTINUATION AND STROKE RISK AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Wang, J.
    Qiao, Y.
    Spivey, C. A.
    Liu, X.
    Phatak, H.
    Mardekian, J.
    Claflin, A. B.
    Kachroo, S.
    Abdulsatter, Y.
    Parker, R. B.
    VALUE IN HEALTH, 2014, 17 (03) : A8 - A9
  • [34] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    BLOOD, 2012, 120 (21)
  • [35] Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation
    Blustin, Jodi M.
    McBane, Robert D.
    Ketha, Siva S.
    Wysokinski, Waldemar E.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (10) : 1129 - 1132
  • [36] Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study
    Farsad, Bahram-Fariborz
    Abbasinazari, Mohammad
    Dabagh, Atousa
    Bakshandeh, Hooman
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (09) : FC4 - FC6
  • [37] Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US
    Schoof, Nils
    Schnee, Janet
    Schneider, Gary
    Gawlik, Melissa
    Zint, Kristina
    Clemens, Andreas
    Bartels, Dorothee B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (05) : 795 - 804
  • [38] Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients
    Lip, G. Y. H.
    Keshishian, A.
    Li, X.
    Lee, T. C.
    Mardekian, J.
    Posner, N.
    Luo, X.
    EUROPEAN HEART JOURNAL, 2017, 38 : 774 - 775
  • [39] Under-use of warfarin for patients with non-valvular atrial fibrillation in Japan
    Inoue, H
    INTERNAL MEDICINE, 2004, 43 (07) : 529 - 530
  • [40] Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Alonso, Alvaro
    JOURNAL OF CARDIOLOGY, 2017, 69 (5-6) : 868 - 876
12345